Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine

N/ANo Longer AvailableNCT00994916

David Lacomis, MD

Overview

The purpose of the study is to provide expanded access (compassionate use) of 3,4 diaminopyridine to patients with Lambert-Eaton myasthenic syndrome (LEMS).

Up to 15 patients over the age of 18 years with a diagnosis of LEMS are eligible to enroll if they are medically stable. They may receive 3,4 diaminopyridine in addition to other treatments and standard of care investigations for LEMS under supervision of the primary investigator. Safety laboratory studies and EKGs will be obtained. The study has been approved by the University of Pittsburgh IRB. There is a local Data-Safety Monitoring Board. The investigator has a hold on enrolling new subjects.

Study Type

EXPANDED_ACCESS

Conditions

Lambert-Eaton Myasthenic Syndrome

Interventions

3,4 diaminopyridineDRUG

3,4 diaminopyridine up to 80 mg daily in divided doses

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Diagnosis of LEMS 2. Over 18 years old 3. Medically stable 4. If female and premenopausal, have a negative urine pregnancy test prior to starting the 3,4 DAP, and, if premenopausal, be willing to practice an effective form of birth control such as "double-barrier contraception" during the study Exclusion Criteria: 1. Known sensitivity to 3,4 DAP 2. History of past or current seizures 3. History of severe asthma 4. Believed by the investigator to be unable to comply with the protocol 5. Unable to provide informed consent

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.